Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
This trial is currently open and accepting patients.
Enrollment: 12 patients (estimated)View More
June 04, 2021
As previously announced, as of the April 14, 2021 data cutoff:
All patients enrolled in the study have poor prognostic factors with 10 of 12 patients penta-refractory and all 12 patients having had at least three prior treatments.
View all clinical trial locations sorted by state.
Read the latest news and updates on this trial.
May 19, 2022
February 28, 2020
October 04, 2019
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message